(Q33319637)

25 July 2017

title

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). (English)

1 reference

25 July 2017

1 reference

acute myeloid leukemia

1 reference

Ruoping Tang

1

1 reference

25 July 2017

Anne-Marie Faussat

2

1 reference

25 July 2017

Jean-Yves Perrot

3

1 reference

25 July 2017

Zora Marjanovic

4

1 reference

25 July 2017

Simy Cohen

5

1 reference

25 July 2017

Thomas Storme

6

1 reference

25 July 2017

Hamid Morjani

7

1 reference

25 July 2017

Ollivier Legrand

8

1 reference

25 July 2017

Jean-Pierre Marie

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

13 February 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

8

1 reference

25 July 2017

page(s)

51

1 reference

Controversies in treatment of AML: case-based discussion

25 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Gefitinib reverses breast cancer resistance protein-mediated drug resistance

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

ABCG2 -- a transporter for all seasons

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

MDR1/P-GP expression as a prognostic factor in acute leukemias.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-51

New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258302

Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18271955

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18271955

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-8-51

1 reference

Dimensions Publication ID

25 July 2017

1037051589

0 references

Fatcat ID

release_3b2bkx3knzaeffljtzmkx42cxi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3b2bkx3knzaeffljtzmkx42cxi

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

2258302

1 reference

25 July 2017

1 reference